Last $168.75 USD
Change Today +1.28 / 0.76%
Volume 973.1K
PCYC On Other Exchanges
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

pharmacyclics inc (PCYC) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/30/15 - $172.11
52 Week Low
05/27/14 - $82.51
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PHARMACYCLICS INC (PCYC)

pharmacyclics inc (PCYC) Related Businessweek News

View More BusinessWeek News

pharmacyclics inc (PCYC) Details

Pharmacyclics, Inc., a biopharmaceutical company, designs, develops, and commercializes small-molecule drugs for the treatment of cancer and immune mediated diseases in the United States and internationally. The company offers IMBRUVICATM as a single agent for the treatment of patients with chronic lymphocytic leukemia who have received at least one prior therapy. Its products candidate in clinical development includes IMBRUVICA BTK inhibitor, which is under multiple Phase I, II, III clinical trials for the treatment of naive and relapsed/refractory chronic lymphocytic leukemia, naive and relapsed/refractory diffuse large B-cell lymphoma, naive follicular lymphoma, relapsed/refractory mantle cell lymphoma, relapsed/refractory follicular lymphoma, relapsed/refractory multiple myeloma, Waldenstrom's macroglobulinemia, and relapsed/refractory marginal zone lymphoma. The company is also developing a BTK inhibitor lead optimization program, which is in Phase I clinical trials targeting anti-inflammatory and autoimmune indications; PCI-27483, an inhibitor of Factor VIIa that is in multiple Phase I, II clinical trials for the treatment of cancer; and PCI-24781, a HDAC inhibitor abexinostat, which is in multiple Phase I, II clinical trials for the treatment of relapsed/refractory lymphomas and solid tumors. The company’s clinical development and product candidates are small-molecule enzyme inhibitors designed to target key biochemical pathways involved in human diseases with critical unmet needs. It has a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize ibrutinib and related compounds; collaboration and license agreement with Les Laboratoires Servier to develop and commercialize abexinostat; and license agreement with Novo Nordisk A/S to research and develop PCI-27483. Pharmacyclics, Inc. was founded in 1991 and is headquartered in Sunnyvale, California.

535 Employees
Last Reported Date: 11/7/14
Founded in 1991

pharmacyclics inc (PCYC) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: --
Chief Financial Officer and Principal Account...
Total Annual Compensation: $541.1K
Chief Operating Officer
Total Annual Compensation: $849.2K
Chief of Quality & Technical Operations
Total Annual Compensation: $704.3K
Compensation as of Fiscal Year 2013.

pharmacyclics inc (PCYC) Key Developments

Pharmacyclics Inc. and Janssen Biotech, Inc. Announce U.S. FDA Approves IMBRUVICA (Ibrutinib) for Treatment of Waldenstrom's Macroglobulinemia

Pharmacyclics, Inc. announced that the U.S. Food and Drug Administration has granted single-agent IMBRUVICA (ibrutinib) regular (full) approval in all lines of therapy as the first and only treatment for patients with Waldenstrom's macroglobulinemia (WM), a rare, indolent type of B-cell lymphoma. This is the fourth indication for IMBRUVICA, an oral therapy, which received FDA Breakthrough Therapy Designation for this indication in February 2013. IMBRUVICA is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc. The approval is based on results from a multi-center, Phase II study that evaluated the efficacy and tolerability of IMBRUVICA in 63 patients with previously treated WM. In this study, IMBRUVICA demonstrated a response rate of 62% according to an Independent Review Committee. Very good partial responses (VGPR) of 11% and partial responses (PR) of 51% were observed. These responses were maintained and the median duration of response (DOR) has not been reached, with a range of 2.8+ to 18.8+ months.

Pharmacyclics, Inc. Announces Preliminary U.S. Net Product Revenue Results for the Fourth Quarter and Fiscal Year Ended December 31, 2014 and Provides U.S. Net Product Revenue Guidance for Fiscal Year 2015

Pharmacyclics Inc. provided preliminary unaudited 2014 U.S. net product revenue results For the fiscal year ended December 31, 2014, U.S. net product revenue for is expected to be approximately $492 million. For the fourth quarter of 2014, U.S. net product revenue is expected to be approximately $185 million, which would represent an approximately 31% sequential increase compared to the quarter ended September 30, 2014. For 2015, the company anticipates U.S. net product revenue of approximately $1 billion for IMBRUVICA, representing a 103% increase over the expected 2014 U.S. net product revenue.

Pharmacyclics Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 02:30 PM

Pharmacyclics Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 02:30 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Robert W. Duggan, Chairman and Chief Executive Officer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PCYC:US $168.75 USD +1.28

PCYC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Celgene Corp $119.16 USD -1.71
View Industry Companies

Industry Analysis


Industry Average

Valuation PCYC Industry Range
Price/Earnings 100.0x
Price/Sales 22.6x
Price/Book 17.7x
Price/Cash Flow 146.2x
TEV/Sales 21.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMACYCLICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at